Background Doryx MPC is a novel Mayne Pharma formulation of the oral tetracycline antimicrobial doxycycline. Doryx MPC has increased acid resistance compared to the standard Doryx tablet, which will minimise oesophageal and stomach dissolution and thus is anticipated to reduce irritation in those regions. The literature is presently void of a population pharmacokinetic analysis of […]
Author: Ashley Hopkins
Time-to-event model of leflunomide cessation due to toxicity in rheumatoid arthritis patients: Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with cessation.
Aim(s) Leflunomide is used in the treatment of rheumatoid arthritis (RA), yet approximately 20 to 40% of patients cease due to toxicity. The aim was to develop a time-to-event model describing leflunomide cessation due to toxicity within a clinical cohort, and to investigate potential predictors of cessation such as total and free teriflunomide exposure and […]
Individualisation of Leflunomide Dosing in Rheumatoid Arthritis Patients : Development of a Semi-Physiologically Based Pharmacokinetic Model
Objective: Following oral administration, leflunomide is rapidly converted to its active metabolite teriflunomide via blood born metabolism and the CYP enzymes 1A2 and 2C19. Variability in enzymatic activity may contribute to the high variability in total teriflunomide concentrations (3 – 150 mg/L) achieved at standard doses. Leflunomide itself is not detectable in the plasma and […]